We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Today's Research Daily features new research reports on 16 major stocks, including Celgene , 21st Century Fox (FOXA - Free Report) and Prudential (PRU - Free Report) .
Shares of Celgene has lost 0.7% year to date, outperforming the Zacks Medical - Biomedical and Genetics sector which has lost 25.2% over the same period. Celgene and other drug makers’ shares have remained under pressure given ongoing questions about pricing issues and other regulatory uncertainties.
These issues notwithstanding, Celgene’s multiple myeloma drug Revlimid continues to grow on the back of market share gains and increased duration. The analyst likes Celgene’s ongoing label expansion efforts and pipeline development. The company anticipates several pipeline-related events over the upcoming quarters and next few years. Celgene’s raised and updated its expectations for both 2016 and 2017, are also encouraging. (You can read the full research report on Celgene here.)
Buy rated 21st Century Fox shares have increased 4.5% year to date, widely outperforming the Zacks Film and Television Production and Distribution sector, which has lost 1.5% over the same period. The analyst likes the company’s Cable Network Programming, which has been its driving force, backed by rising affiliate fees.
Earlier, the company said that the pace of affiliate fees will accelerate in the back half of the fiscal year as 15–20% of the company’s domestic subscribers will be up for annual renewal in couple of years. Moreover, increase in content revenues at the Filmed Entertainment segment is also boosting the company’s overall performance. (You can read the full research report on 21st Century Fox here.)
Buy rated Prudential shares have gained 30.5% year to date, widely outperforming the Zacks Insurance - Multi line sector, which has gained 12.7% over the same period. The analyst likes its high performing asset management business, widespread international operations and deeper reach in the pension risk transfer market. It has been growing its pension risk transfer business and has more than $75 billion in pension account values.
Expanded international presence, mainly in Japan, Korea and China, provides it with better organic growth opportunities than peers. A strong balance sheet and efficient capital management are other tailwinds. (You can read the full research report on Prudential here.)
Other noteworthy reports we are featuring today include Royal Dutch Shell , Amazon (AMZN - Free Report) and Exelon (EXC - Free Report) .
Free Access: All Zacks Research Reports Starting today, you are invited to download in-depth analysis reports covering more than 1,000 of the most widely followed stocks. Valued at $25 each, they are yours to consult over the next 30 days absolutely free. They feature sensitive Zacks Rank information on each stock that you won't find anywhere else. See the reports free >>
Mark Vickery
Senior Editor
Note: If you want an email notification each time Zacks Director of Research Sheraz Mian publishes a new article, pleaseclick here>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Top Research Reports for December 28, 2016
Wednesday, December 28, 2016
Today's Research Daily features new research reports on 16 major stocks, including Celgene , 21st Century Fox (FOXA - Free Report) and Prudential (PRU - Free Report) .
Shares of Celgene has lost 0.7% year to date, outperforming the Zacks Medical - Biomedical and Genetics sector which has lost 25.2% over the same period. Celgene and other drug makers’ shares have remained under pressure given ongoing questions about pricing issues and other regulatory uncertainties.
These issues notwithstanding, Celgene’s multiple myeloma drug Revlimid continues to grow on the back of market share gains and increased duration. The analyst likes Celgene’s ongoing label expansion efforts and pipeline development. The company anticipates several pipeline-related events over the upcoming quarters and next few years. Celgene’s raised and updated its expectations for both 2016 and 2017, are also encouraging. (You can read the full research report on Celgene here.)
Buy rated 21st Century Fox shares have increased 4.5% year to date, widely outperforming the Zacks Film and Television Production and Distribution sector, which has lost 1.5% over the same period. The analyst likes the company’s Cable Network Programming, which has been its driving force, backed by rising affiliate fees.
Earlier, the company said that the pace of affiliate fees will accelerate in the back half of the fiscal year as 15–20% of the company’s domestic subscribers will be up for annual renewal in couple of years. Moreover, increase in content revenues at the Filmed Entertainment segment is also boosting the company’s overall performance. (You can read the full research report on 21st Century Fox here.)
Buy rated Prudential shares have gained 30.5% year to date, widely outperforming the Zacks Insurance - Multi line sector, which has gained 12.7% over the same period. The analyst likes its high performing asset management business, widespread international operations and deeper reach in the pension risk transfer market. It has been growing its pension risk transfer business and has more than $75 billion in pension account values.
Expanded international presence, mainly in Japan, Korea and China, provides it with better organic growth opportunities than peers. A strong balance sheet and efficient capital management are other tailwinds. (You can read the full research report on Prudential here.)
Other noteworthy reports we are featuring today include Royal Dutch Shell , Amazon (AMZN - Free Report) and Exelon (EXC - Free Report) .
Free Access: All Zacks Research Reports
Starting today, you are invited to download in-depth analysis reports covering more than 1,000 of the most widely followed stocks. Valued at $25 each, they are yours to consult over the next 30 days absolutely free. They feature sensitive Zacks Rank information on each stock that you won't find anywhere else. See the reports free >>
Mark Vickery
Senior Editor
Note: If you want an email notification each time Zacks Director of Research Sheraz Mian publishes a new article, please click here>>>